Biogen Idec Announces Webcast of Hemophilia R&D Roundtable

Wednesday, August 31, 2011 4:01 pm EDT

Dateline:

WESTON, Mass.

Public Company Information:

NASDAQ:
BIIB
US09062X1037

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec Inc. (NASDAQ: BIIB) announced today that its Hemophilia R&D Roundtable will be webcast live on Monday, September 12, 2011 at 8:00 a.m. ET. To access the live webcast, please visit Biogen Idec’s Investor Relations section (investor.biogenidec.com). An archived version of the webcast will be available for 14 days following the presentation.

About Biogen Idec

Biogen Idec uses cutting-edge science to discover, develop, manufacture and market therapies for serious diseases with a focus on neurology, immunology and hemophilia. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than $4 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Contact:

Biogen Idec
Karen Jewell, 781-464-2066
Investor Relations